Innovation Meets Accessibility: Lupin’s Latest Launch Targets Type 2 Diabetes

Lupin’s latest launch marks a significant milestone in its U.S. generics strategy. The tablets, available in multiple dosage strengths, aim to provide affordable treatment options for patients managing type 2 diabetes.  

Key highlights  

• Lupin launches Dapagliflozin and Metformin Hydrochloride ER tablets in U.S.  
• FDA approval confirms bioequivalence to Xigduo XR  
• Available in four dosage strengths for type 2 diabetes management  
• Strengthens Lupin’s U.S. generics portfolio in anti-diabetic therapy  
  
  

Sources: Lupin Press Release